Quality of life in allergic rhinitis
- PMID: 10582730
- DOI: 10.1016/S1081-1206(10)62850-5
Quality of life in allergic rhinitis
Abstract
Objective: This review will furnish the reader current information on the importance of quality of life evaluation in patients suffering from allergic rhinitis, the different types of quality of life instruments used, and how they can be used in judging different pharmaceutical therapies.
Data sources: Computer-assisted MEDLINE searches for articles assessing "quality of life" and "outcomes" in rhinitis. Also MEDLINE searches evaluating health-related quality of life in relationship to different pharmacologic treatments in allergic rhinitis.
Study selections: Pertinent abstracts and articles in two broad areas were selected. The first groups were articles in the fields of outcomes, quality of life, allergic rhinitis, and its relationship to health-related quality of life. The second group of articles evaluated different pharmacologic agents' effect on the health-related quality of life of rhinitis patients. Both sets of articles were critically analyzed with important representative studies selected for this review.
Results: Health-related quality of life of patients with allergic rhinitis is impaired as measured by both generic and specific health-related quality of life instruments. Use of second generation antihistamines, intranasal corticosteroids, and intranasal ipratropium bromide have been shown to improve the health-related quality of life of sufferers of allergic rhinitis.
Conclusions: The measuring of health-related quality of life is assuming a primary position in outcomes analysis in the patient with allergic rhinitis. Studies have documented the validity of using generic and specific health-related quality of life instruments in allergic rhinitis. Each type has its own weaknesses and strengths that the user needs to appreciate. Appraising the role of different pharmacologic agents in allergic rhinitis in improving the patient's quality of life is an important part of proving the medication's worth to the health care community.
Similar articles
-
Quality of life in patients with allergic rhinitis.Ann Allergy Asthma Immunol. 2000 Nov;85(5):338-47; quiz 347-8. doi: 10.1016/S1081-1206(10)62543-4. Ann Allergy Asthma Immunol. 2000. PMID: 11101172 Review.
-
Clinical outcomes and adverse effect monitoring in allergic rhinitis.J Allergy Clin Immunol. 2005 Mar;115(3 Suppl 1):S390-413. doi: 10.1016/j.jaci.2004.12.014. J Allergy Clin Immunol. 2005. PMID: 15746880 Review.
-
Allergic rhinitis: the impact of discordant perspectives of patient and physician on treatment decisions.Clin Ther. 2007 Jul;29(7):1428-40. doi: 10.1016/j.clinthera.2007.07.013. Clin Ther. 2007. PMID: 17825694
-
Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments.Ann Allergy Asthma Immunol. 2003 Feb;90(2):182-90; quiz 190-1, 232. doi: 10.1016/S1081-1206(10)62138-2. Ann Allergy Asthma Immunol. 2003. PMID: 12602664 Review.
-
ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review.Allergy. 2008 Jun;63(6):660-9. doi: 10.1111/j.1398-9995.2008.01649.x. Allergy. 2008. PMID: 18445183 Review.
Cited by
-
Investigation of the relationship between allergic rhinitis and personality traits using semeiometry.Hippokratia. 2007 Jul;11(3):138-41. Hippokratia. 2007. PMID: 19582208 Free PMC article.
-
Impact of sleep as a specific marker of quality of life in allergic rhinitis.Curr Allergy Asthma Rep. 2013 Apr;13(2):131-41. doi: 10.1007/s11882-012-0330-z. Curr Allergy Asthma Rep. 2013. PMID: 23247762 Review.
-
Selecting the optimal oral antihistamine for patients with allergic rhinitis.Drugs. 2006;66(18):2309-19. doi: 10.2165/00003495-200666180-00004. Drugs. 2006. PMID: 17181374 Review.
-
Efficacy and safety of ketotifen eye drops as adjunctive therapy to mometasone nasal spray in subjects with seasonal allergic rhinoconjunctivitis.Clin Drug Investig. 2003;23(9):597-604. doi: 10.2165/00044011-200323090-00006. Clin Drug Investig. 2003. PMID: 17535073
-
Omalizumab in asthma: approval and postapproval experience.Clin Rev Allergy Immunol. 2005 Aug;29(1):3-16. doi: 10.1385/CRIAI:29:1:003. Clin Rev Allergy Immunol. 2005. PMID: 16222080 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical